The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
Göran Tornling, Rohit Batta, View ORCID ProfileJoanna Porter, Thomas Bengtsson, Kartikeya Parmar, Reema Kashiva, Anders Hallberg, Anne Katrine Cohrt, Kate Westergaard, Carl-Johan Dalsgaard, Johan Raud
doi: https://doi.org/10.1101/2021.01.26.21250511
Göran Tornling
1Respiratory Medicine Division, Department of Medicine Solna, Karolinska Institutet, SE-171 77 Stockholm, Sweden
Rohit Batta
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
Joanna Porter
3UCL Respiratory, University College London & Department of Thoracic Medicine, University College Hospitals London, London NW1 2PG, UK
Thomas Bengtsson
4StatMind AB, Scheelevägen 17, SE-223 70 LUND, Sweden
Kartikeya Parmar
5Department of Medicine, Nodal officer at 1200-bed COVID-19 hospital, Civil Hospital and B J Medical College, Asarwa, Ahmedabad GUJARAT, India 380016
Reema Kashiva
6Department of Medicine, Noble Hospitals Pvt. Ltd, 153 Magarpatta City Road, Hadapsar, Pune MAHARASHTRA, India 411013
Anders Hallberg
7Department of Medicinal Chemistry, Uppsala University, SE-751 23 Uppsala, Sweden
Anne Katrine Cohrt
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
Kate Westergaard
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
Carl-Johan Dalsgaard
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
Johan Raud
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
8Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden
Data Availability
Data will be made available to researchers who provide a scientifically sound proposal. Proposals should be directed to carl-johan.dalsgaard@vicorepharma.com
Posted January 28, 2021.
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
Göran Tornling, Rohit Batta, Joanna Porter, Thomas Bengtsson, Kartikeya Parmar, Reema Kashiva, Anders Hallberg, Anne Katrine Cohrt, Kate Westergaard, Carl-Johan Dalsgaard, Johan Raud
medRxiv 2021.01.26.21250511; doi: https://doi.org/10.1101/2021.01.26.21250511
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
Göran Tornling, Rohit Batta, Joanna Porter, Thomas Bengtsson, Kartikeya Parmar, Reema Kashiva, Anders Hallberg, Anne Katrine Cohrt, Kate Westergaard, Carl-Johan Dalsgaard, Johan Raud
medRxiv 2021.01.26.21250511; doi: https://doi.org/10.1101/2021.01.26.21250511
Subject Area
Subject Areas
- Addiction Medicine (395)
- Allergy and Immunology (707)
- Anesthesia (198)
- Cardiovascular Medicine (2893)
- Dermatology (248)
- Emergency Medicine (434)
- Epidemiology (12652)
- Forensic Medicine (10)
- Gastroenterology (816)
- Genetic and Genomic Medicine (4511)
- Geriatric Medicine (411)
- Health Economics (720)
- Health Informatics (2882)
- Health Policy (1061)
- Hematology (381)
- HIV/AIDS (915)
- Medical Education (419)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4277)
- Nursing (230)
- Nutrition (628)
- Oncology (2244)
- Ophthalmology (638)
- Orthopedics (256)
- Otolaryngology (323)
- Pain Medicine (273)
- Palliative Medicine (83)
- Pathology (491)
- Pediatrics (1185)
- Primary Care Research (490)
- Public and Global Health (6858)
- Radiology and Imaging (1508)
- Respiratory Medicine (910)
- Rheumatology (432)
- Sports Medicine (379)
- Surgery (477)
- Toxicology (60)
- Transplantation (206)
- Urology (176)